Imed AB
http://www.imed.se
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Imed AB
MedImmune Leverages Spirogen Tech In ADC Collaboration With Tanabe
MedImmune LLC is combining the second-generation pyrollobenzodiazepine (PBD) warheads it picked up in a 2013 buyout of Spirogen Ltd. with Tanabe Research Laboratories USA Inc.'s antibodies in a collaboration to develop mono-specific and bi-specific antibody-drug conjugates (ADCs) against a set of cancer targets.
AstraZeneca bolsters heart failure and metabolic disease research
AstraZeneca and its MedImmune unit have signed a couple of early stage research deals aimed at boosting their cardiovascular and metabolic pipeline efforts – one of its three core therapeutic areas.
Ebola – the industry's response in antivirals
The unprecedented scale of the Ebola epidemic in West Africa has prompted a similarly unprecedented interest in the response from the pharma and biotech industries to develop treatments and vaccines against the virus.
Soriot talks up an independent AstraZeneca
CEO Pascal Soriot used AstraZeneca's R&D day to talk up the company's rosy prospects as an independent company. Although the likelihood of a renewed takeover bid by Pfizer looks to be waning, he is taking no chances, and at the meeting with investors R&D leaders from across the company took to the podium to explain how bright the company's future looks.
Company Information
- Industry
- Pharmaceuticals
-
Biotechnology
-
Large Molecule
- Antibodies
-
Large Molecule
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice